BOSTON ( TheStreet) -- Welcome to the doubleheader FDA advisory panel live blog: The morning panel features Aveo Oncology ( AVEO) and its kidney cancer drug tivozanib. In the afternoon session, Delcath Systems ( DCTH) brings the Melblez liver-tumor therapy in front of the FDA's outside experts. The panel experts will consider the efficacy and safety of tivozanib and Melblez and vote to recommend approval -- or not. The final approval decision rests with the FDA. Expect trading in both Aveo and Delcath to be halted during their respective panel sessions. Both stocks have been under pressure this week on FDA reviews which raised concerns and questions about the clinical benefit and/or safety of tivozanib and Melblez. It will be the job of Aveo and Delcath to counter these concerns and convince the panel members that their respective products deserve FDA approval. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.